Develops disease‑modifying ophthalmic therapeutics: one candidate targets glaucoma neurodegeneration with neuroprotective effects and substantial intraocular‑pressure reduction. Second candidate targets retinal diseases (diabetic retinopathy, diabetic macular edema, and wet/dry age‑related macular degeneration) as a potential first‑in‑class therapy and is in IND‑enabling activities.